How Personalised Should Neoantigen-Targeted Cell Therapies & Cancer Vaccines Be? Unravelling the Limitations of Precision Neoantigen Therapies & Exploring Shared-Neoantigens for an Off-The-Shelf Approach
Time: 2:30 pm
day: Pre-Conference Day
Details:
Personalised therapies hold promise to provide the most optimal treatment plan available to patients, overcoming tumour heterogeneity and resistance. However, identifying specific neoantigens and developing precision therapies incurs a high cost, complex logistical planning, and a lengthy timeframe which is often too great for patients with late-stage disease. As such, the feasibility and scalability of personalised therapies is uncertain.
Identifying shared neoantigens and developing off-the-shelf neoantigen therapies for small groups of patients could help overcome these challenges. Can allogenic therapies hold up against the precision of personalised therapies?
This workshop will delve into:
- The feasibility and scalability of personalised neoantigen therapies, considering the expense and logistics of manufacturing therapies for one person, the cost on patient health of delaying treatment, and health equity
- Identifying shared neoantigens and hotspot mutations in subsets of patients for the development of small-group off-the-shelf neoantigen vaccines and cell therapies
- Should neoantigen therapies be developed for individuals, small groups with shared neoantigens, or be truly off-the-shelf?
